Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CHU de Quebec-Universite Laval
Age
18–100
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients must have a histologically or cytologically confirmed history of adenocarcinoma of the prostate.
Patients must have a PSA failure defined as PSA of \>= 0.5 ng/ml that has increased above nadir following radical prostatectomy (RP); or a PSA increase of 2.0 above post-therapy nadir after radiotherapy (RT); or a PSA increase between 0.05-0.49 ng/ml that has increased above nadir following RP. The maximal PSA value at enrolment must be \<5.0 ng/mL after RP and \<6 ng/mL after RT.
PSA value must be increasing based on three consecutive measurements each separated by at least 4 weeks prior to enrolment to this study.
Patients may have received any number of local therapies (RP, external beam RT or brachytherapy).
Provide written informed consent.
You may not be if
Patients with evidence of metastatic disease.
Patients who have received prior cytotoxic chemotherapy for recurrent disease.
Patients currently receiving biological response modifiers, or corticosteroids.
Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social situations that would limit compliance with study requirements.
Use of omega-3 or any other dietary supplements for the previous 3 months and during study is not allowed.
